Biosimilars in oncology: EHA 2017 session on rituximab
Can the dream of affordable cancer care come true?
Biosimilars: informing patients and physicians
Biosimilars - the question of trials and approval
Are combination therapies more efective for the treatment of relapsed refractory CLL?